Biocryst Pharmaceuticals market cap BCRX

Share price times shares outstanding: what the whole company sells for, since 2011.

Biocryst Pharmaceuticals is worth $2B at the close on Oct 23, 2026, at $7.65 a share.

That is up 29% over the last year and down 27% over five years.

Its highest close in our data was $3.4B in Feb 2022.

Market cap over time

Year	End of year	Low	High	Change
2026 so far	$2B	$1.3B	$2.7B	+22%
2025	$1.6B	$1.4B	$2.3B	+1%
2024	$1.6B	$857.6M	$1.8B	+30%
2023	$1.2B	$1B	$2.2B	−43%
2022	$2.1B	$1.6B	$3.4B	−14%
2021	$2.5B	$1.4B	$3.1B	+89%
2020	$1.3B	$281.6M	$1.5B	+282%
2019	$344.6M	$193.3M	$1.1B	−60%
2018	$864M	$428.1M	$1B	+79%
2017	$483.2M	$329.8M	$656.7M	+3%
2016	$466.9M	$125.4M	$623.4M	−38%
2015	$756.8M	$600.3M	$1.2B	−12%
2014	$863.1M	$462.5M	$1B	+95%
2013	$443.2M	$60.5M	$443.2M	+522%
2012	$71.2M	$64.1M	$257.4M	−36%
2011	$111.7M	$111.1M	$145.8M	n/a

Companies in Biotechnology nearest Biocryst Pharmaceuticals' size, closest first, today.

Company	Market cap
BCRXBiocryst Pharmaceuticals	$2B
VCELVericel	$2.2B
ADMAAdma Biologics	$2.4B
MGTXMeiraGTx	$884.6M
KRYSKrystal Biotech	$9.2B
RGENRepligen	$10B
TECHBIO-TECHNE	$11.4B
HALOHalozyme Therapeutics	$14.3B
NBIXNeurocrine Biosciences	$14.5B
EXELExelixis	$16B
PLXProtalix BioTherapeutics	$205.5M
Peer median	$9.6B